CORRECTION article

Front. Oncol., 31 May 2023

Sec. Gynecological Oncology

Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1228879

Corrigendum: Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022

  • Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, China

In the published article, there was an error in the Funding statement. In the Funding statement, we left out a funding. The original Funding statement is “This work was supported by grants from the National Natural Science Foundation of China (No. 81873195), the Liaoning Revitalization Talents Program (XLYC1907113), the Natural Science Foundation of Liaoning Province (2023010109-JH2/1013), and the Distinguished Young Scholars in Dalian (2022RJ19).”. The correct Funding statement appears below.

Funding

This work was supported by grants from the National Natural Science Foundation of China (No.81873195), the Liaoning Revitalization Talents Program (XLYC1907113), the Natural Science Foundation of Liaoning Province (2023010109-JH2/1013), the Distinguished Young Scholars in Dalian (2022RJ19), and the Dalian Medical University Foundation for Teaching Reform Project of Undergraduate Innovative Talents Training (111906010210).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

drug resistance, ovarian cancer, bibliometric, Citespace, Vosviewer, PARP inhibitors, bevacizumab

Citation

Liu J, Ma J, Zhang J, Li C, Yu B, Choe HC, Ding K, Zhang L and Zhang L (2023) Corrigendum: Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022. Front. Oncol. 13:1228879. doi: 10.3389/fonc.2023.1228879

Received

25 May 2023

Accepted

26 May 2023

Published

31 May 2023

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2023

Updates

Copyright

*Correspondence: Lin Zhang,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics